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Abstract
Background: In	patients	with	bronchial	asthma	and	those	with	chronic	obstructive	
pulmonary	disease	(COPD),	inhalation	therapy	and	rinsing	of	the	mouth	and	the	oro-
pharynx	by	gargling	(“RMOG”)	after	inhalation	are	recommended.	We	performed	a	
cross-sectional	audit	aimed	at	investigating	(a)	the	proportion	of	patients	performing	
“RMOG”	after	inhalation	and	(b)	storage	place	of	patients’	inhaler.
Methods: Patients	with	bronchial	asthma	and	those	with	COPD	were	asked	by	medi-
cal	 aids	 at	 outpatient	 visits	whether	 they	did	 “RMOG	every	 time,”	 “RMOG	some-
times,”	or	“no	RMOG”	after	inhalation,	and	where	they	stored	their	inhaler.
Results: During	a	six	month	study	period	up	to	September	2017,	330	consecutive	
patients	with	asthma	and	those	with	COPD	were	included	in	the	study.	Two	hundred	
and	 thirty-two	 (70.3%)	of	 the	330	patients	 answered	 “RMOG	every	 time”	 and	98	
(29.7%)	of	them	did	“RMOG	sometimes”	and	did	“no	RMOG.”	There	was	a	difference	
in	 the	proportion	of	patients	performing	RMOG	after	 inhalation	with	patient	 age.	
With	regard	to	the	storage	location	of	inhaler,	we	found	the	proportion	of	patients	
performing	RMOG	was	higher	in	those	who	stored	inhalers	in	a	room	with	running	
water	than	in	those	who	stored	inhalers	at	other	places.	This	difference	was	found	in	
patients	with	both	bronchial	asthma	and	those	with	COPD.
Conclusions: Further	 implementation	of	“patient	education”	on	performing	RMOG	
after	 inhalation	for	patients	receiving	 inhaled	medication	 is	still	necessary.	Our	re-
sults	suggest	that	it	is	better	to	store	inhalers	in	places	where	there	is	easy	access	to	
tap	water	used	for	RMOG.
K E Y W O R D S
allergy,	bronchial	asthma,	chronic	obstructive	respiratory	disease,	rinsing	of	oropharynx,	
storage	place	of	inhaler
102  |     OKAUCHI et Al.
1  | INTRODUC TION
At	 present,	 inhaled	 corticosteroid	 (ICS),	 long-acting	 beta-agonist	
(LABA),	combination	of	ICS	and	LABA	(ICS/LABA),	long-acting	mus-
carinic	 antagonist	 (LAMA),	 and	 combination	 of	 LAMA	 and	 LABA	
(LAMA/LABA)	 are	 the	 most	 common	 drugs	 for	 bronchial	 asthma	
and	chronic	obstructive	pulmonary	disease	(COPD).1	It	is	well	known	
that	ICS	may	cause	local	adverse	events	(AEs),	such	as	oropharyngeal	
candidiasis	and	hoarseness	of	the	voice.2,3	Inhaled	beta-adrenergic	
stimulation	may	increase	heart	rate	and	the	potential	for	cardiac	ar-
rhythmias.4,5	As	rinsing	of	the	mouth	and	the	oropharynx	by	gargling	
(RMOG)	after	inhalation	is	effective	for	prevention	of	local	adverse	
effects,	such	as	hoarseness	and	oropharyngeal	candidiasis,	RMOG	
is	 recommended	 to	 remove	 inhaled	 drugs,	 such	 as	 ICS,	 deposited	
on	the	oropharyngeal	mucosa.6	In	addition,	dry	mouth	is	one	of	the	
treatment-related	 AEs	 in	 patients	 treated	with	 inhaled	 LAMA,	 al-
though	the	incidence	is	low.7‒9	There	is	no	rationale	for	RMOG	after	
inhalation	of	LAMAs.	It	is	not	necessary	to	recommend	RMOG	for	all	
patients	inhaling	only	LAMA.	However,	some	patients	who	inhaled	
LAMA	alone	require	ICS	or	LABA	during	their	clinical	courses.	If	side	
effects	occur,	a	considerable	number	of	patients	will	 refuse	taking	
inhaled	medicine.	Therefore,	 in	 Japan,	physicians	 in	 several	hospi-
tals	 recommend	 uniformly	 performing	RMOG	 to	 all	 patients	 after	
inhalation,10‒12	and	some	package	inserts	of	LAMAs	contain	RMOG	
recommendations.13,14
Asthma	and	COPD	are	both	highly	prevalent	conditions	that	can	
coexist	in	the	same	individual.15	COPD	guidelines	suggest	using	ICSs	
in	patients	with	severe	airflow	limitation	or	those	at	high	risk	of	exac-
erbations.16	It	is	not	clear	whether	it	is	necessary	for	LAMA,	and	the	
package	labeling	of	LAMAs	does	not	recommend	gargling.	Although	
there	is	no	recommendation	for	gargling	with	LAMA	inhalation,	ICS	
and	ICS/LABA	can	be	prescribed,	not	only	for	patients	with	asthma,	
but	also	for	those	with	COPD.	If	it	is	evaluated	that	there	is	a	coex-
isting	asthma	condition	 in	patients	with	COPD,	 inhaled	medicines,	
including	ICS,	will	be	prescribed.	In	addition,	it	is	possible	that	triple	
inhaled	combination	of	LAMA,	ICS,	and	LABA	will	be	administered	in	
patients	with	asthma	and	those	with	COPD.	Therefore,	it	is	realistic	
to	instruct	“carry	out	gargling	after	medicine	inhalation”	rather	than	
instructing	separately	whether	to	perform	gargling	or	not	depending	
on	a	difference	 in	disease	or	drugs.	 In	 this	study,	patient	behavior	
was	evaluated	from	the	viewpoint	that	it	is	desirable	to	gargle	after	
inhalation.
In	 clinical	 practice,	 there	 has	 been	 no	 report	 that	 examined	
the	 proportion	 of	 patients	 performing	 RMOG	 while	 consider-
ing	 the	 storage	 location	 of	 the	 inhaler.	 To	 clarify	 the	 proportion	
of	patients	performing	RMOG	after	 inhalation	in	clinical	practice,	
we	performed	a	survey	at	three	tertiary	hospitals	in	Japan.	In	ad-
dition	 to	 this,	we	 investigated	where	 the	 inhaler	was	 stored,	and	
whether	 there	 was	 relationship	 between	 storage	 location	 and	 if	
patients	were	 performing	 the	 RMOG.	 The	 findings	 of	 this	 study	
may	provide	useful	information	to	mitigate	the	local	AEs	of	inhaled	
medications.
2  | MATERIAL S AND METHODS
2.1 | Patients and methods
This	was	 a	 cross-sectional	 audit	was	 conducted	 at	 three	hospitals	
(Mito	Medical	 Center,	 University	 of	 Tsukuba-Mito	 Kyodo	General	
Hospital,	 Hitachinaka	 General	 Hospital,	 and	 Ryugasaki	 Saiseikai	
Hospital)	between	April	2016	and	September	2017.
In	order	to	avoid	“interviewer	bias”	and	“following	bias”,17 inter-
views	of	patients	were	not	performed	by	attending	chest	physician	
in	 charge	of	 treatment,	 but	 rather	 by	medical	 aids	without	 a	 con-
flict	of	interest	with	patients	to	be	interviewed.	At	outpatient	visit,	
TA B L E  1  Characteristics	of	330	patients	with	bronchial	asthma	
and	those	with	chronic	obstructive	pulmonary	disease
Age	(y) Median:	72,	range:	26-95
Gender
Male	:	female 215	(65.2%):115	(34.8%)
Pulmonary	disease
Bronchial	asthma:	COPD 222	(67.3%):108	(32.7%)
Detailed	inhaler	drugs
ICS 22	(22	patients	with	BA)
ICS/LABA 153	(145	patients	with	BA,	
eight	patients	with	COPD)
ICS/LABA+LAMA 60	(50	patients	with	BA,	
10	patients	with	COPD)
SABA 1	(one	patient	with	BA)
LABA 1	(one	patient	with	COPD)
LAMA 30	(four	patients	with	BA,	
26	patients	with	COPD)
LAMA/LABA 63	(63	patients	with	COPD)
RMOG
RMOG	every	time 232	(70.3%)
RMOG	sometimes,	No	RMOG 33	(10.0%),	65	(19.7%)
Storage	place	of	inhaler
Living	room 152	(46.1%)
Room with running water 127	(38.5%)
Bedroom 26	(7.9%)
Other	places 25	(7.5%)
RMOG	and	storage	place	of	inhaler
Room with running water
RMOG	every	time 109	(85.8%)
RMOG	sometimes	and	no	RMOG 18	(14.2%)
Other	places	than	a	room	with	running	water
RMOG	every	time 123	(60.6%)
RMOG	sometimes	and	no	RMOG 80	(39.4%)
COPD,	chronic	obstructive	pulmonary	disease;	ICS,	inhaled	corticoster-
oid;	ICS/LABA,	combination	of	ICS	and	LABA;	LABA,	long-acting	beta-
agonist;	 LAMA,	 long-acting	 muscarinic	 antagonist;	 LAMA/LABA,	
combination	of	LAMA	and	LABA;	RMOG,	rinsing	of	the	mouth	and	the	
oropharynx	by	gargling;	SABA,	short-acting	beta-agonist.
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patients	 were	 asked	 two	 questions:	 (a)	 whether	 they	 did	 “RMOG	
every	 time,”	 “RMOG	 sometimes,”	 or	 “no	 RMOG”	 after	 inhalation,	
and	(b)	where	they	stored	their	 inhaler.	As	far	as	possible	to	avoid	
speculation	during	the	 interview	of	each	patient,	we	did	not	spec-
ify	details	such	as	water	or	mouthwash,	 the	number	of	gargles,	or	
time	of	gargling.	Eligible	patients	were	those	with	bronchial	asthma	
or	those	with	COPD	more	than	20	years	old,	treated	with	 inhalers	
with	 ICS,	 ICS/LABA,	 LAMA,	 ICS/LABA+LAMA,	 and	 LAMA/LABA	
for	more	than	three	months.
2.2 | Ethics committee approval
All	enrolled	patients	provided	written	informed	consent.	This	study	
was	approved	by	the	Hospital's	Ethics	Committee	of	Mito	Medical	
Center,	 University	 of	 Tsukuba-Mito	 Kyodo	 General	 Hospital	 (NO	
16-39).
2.3 | Statistical analysis
Differences	between	 the	distributions	of	 subpopulations	between	
each	group	were	analyzed	using	chi-square	test.	All	statistical	analy-
ses	were	performed	using	SPSS	10.1	for	Windows,	and	P	<0.05	was	
considered	a	statistically	significant	result.
3  | RESULTS
3.1 | The patient cohort
During	 the	 study	 period,	 all	 the	 consecutive	 330	 patients	 with	
bronchial	 asthma	 or	 COPD,	 who	 agreed	 with	 the	 participation	 in	
this	study,	were	 included.	The	patient	characteristics	are	shown	in	
Table 1. Two hundred and fifteen were male and 115 were female. 
The	 median	 age	 was	 72	years	 (range,	 26-95	years).	 Two	 hundred	
and	twenty-two	patients	had	bronchial	asthma	and	108	had	COPD.	
Twenty-two	patients	had	ICS,	153	had	ICS/LABA,	60	had	ICS/LABA	
+	LAMA,	29	had	LAMA,	and	63	had	LAMA/LABA.
Of	330	patients,	232	(70.3%)	patients	performed	“RMOG	every	
time,”	10.0%	performed	“RMOG	sometimes,”	and	19.7%	performed	
“no	RMOG.”	The	proportion	of	 “RMOG	every	 time”	was	82.0%	 in	
patients	with	bronchial	asthma	and	46.3%	 in	patients	with	COPD.	
The	proportion	of	“RMOG	every	time”	in	female	patients	(85.2%,	98	
of	115	patients)	was	higher	than	that	of	male	patients	(62.3%,	134	
of	 215	patients;	P = 0.0001).	But	 the	proportion	of	 “RMOG	every	
time”	in	patients	over	75	years	of	age	(68.9%,	91	of	132	patients)	was	
not	different	to	those	under	75	years	of	age.	(71.2%,	141	of	198	pa-
tients;	P = 0.713).	The	proportion	of	“RMOG	every	time”	in	patients	
treated	with	ICS-containing	inhalation	(83.0%,	195	of	235	patients)	
was	higher	than	in	those	treated	without	ICS-containing	inhalation	
(38.9%,	37	of	95	patients;	P = 0.0001).
Table	2	shows	a	comparison	of	clinical	information	between	232	
patients	who	answered	they	did	“RMOG	every	time”	and	98	patients	
who	answered	“RMOG	sometimes”	or	“no	RMOG.”	The	proportion	
of	“RMOG	every	time”	was	higher	in	patients	with	bronchial	asthma,	
female	gender,	patients	treated	with	ICS-containing	inhalation,	and	
patients	 treated	with	 LAMA	and	other	drug-containing	 inhalation.	
In	 addition,	 the	 proportion	 of	 “RMOG	 every	 time”	 was	 higher	 in	
patients	who	stored	 inhaler	 in	a	 room	with	 running	water	 such	as	
kitchen	or	bathroom	than	in	patients	who	stored	inhalers	in	a	room	
with	running	water	such	as	kitchen	or	bathroom.
Table	3	shows	a	comparison	of	clinical	information	between	222	
patients	with	bronchial	 asthma	and	108	patients	with	COPD.	The	
proportion	of	“RMOG	every	time”	was	higher	in	female	gender,	pa-
tients	 treated	with	 ICS-containing	 inhalation,	 and	patients	 treated	
with	LAMA	and	other	drug-containing	inhalation.	There	was	no	dif-
ference	in	the	inhaler	storage	place	in	patients	with	bronchial	asthma	
and	those	with	COPD.
Number of patients who answered they did
“RMOG every time”
“RMOG sometimes” or 
“no RMOG” P‐value
Age	(median,	range),	(y) 73,	26-93 71,	41-95 0.4046
Gender,	M/F 134/98 81/17 0.0001
Diagnosis
Asthma/COPD 182/50 40/58 0.0001
ICS-containing	drugs
Included/not included 195/37 40/58 0.0163
LAMA
LAMA	only/LAMA	and	
other	drugs
8/224 21/77 0.0001
Storage	place
Room with running 
water/other	places
109/123 18/80 0.0001
COPD,	chronic	obstructive	pulmonary	disease,	ICS,	inhaled	corticosteroid,	LAMA,	long-acting	mus-
carinic	antagonist,	RMOG	rinsing	of	the	mouth	and	the	oropharynx	by	gargling.
TA B L E  2  Comparison	between	232	
patients	who	answered	they	did	“RMOG	
every	time”	and	98	patients	who	
answered	they	did	“RMOG	sometimes”	or	
“no	RMOG”
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Table	4	shows	the	proportion	of	“RMOG	every	time”	and	“RMOG	
sometimes”	or	 “no	RMOG”	 in	222	patients	with	bronchial	asthma.	
The	proportion	of	“RMOG	every	time”	was	higher	in	female	gender	
and	 patients	 treated	 with	 ICS-containing	 inhalation,	 respectively.	
There	 was	 a	 significant	 difference	 in	 the	 inhaler	 storage	 place	 in	
these	patients.
Table	5	shows	the	proportion	of	“RMOG	every	time”	and	“RMOG	
sometimes”	 or	 “no	 RMOG”	 in	 108	 patients	 with	 COPD.	 “RMOG	
every	 time”	was	higher	 in	patients	 treated	with	 ICS-containing	 in-
halation,	and	patients	treated	with	LAMA	and	other	drug-containing	
inhalation,	respectively.	There	was	a	significant	difference	in	the	in-
haler	storage	place	in	these	patients.
4  | DISCUSSION
In	the	present	study,	we	investigated	(a)	the	proportion	of	perform-
ing	 “RMOG”	after	 inhalation	and	 (b)	 the	 storage	place	of	patients’	
inhalers.	Herein,	we	show	four	interesting	findings.	First,	the	propor-
tion	of	patients	who	answered	they	“always	did	RMOG”	was	70.3%.	
Ten	percent	and	19.7%	of	them	answered	they	performed	“RMOG	
sometimes”	and	did	“no		RMOG,”	respectively.	Second,	the	propor-
tion	of	 “RMOG	every	 time”	was	more	 than	 two-thirds	 of	 patients	
with	bronchial	asthma,	but	less	than	half	of	patients	with	COPD.	For	
both	diseases,	the	proportion	of	patients	with	“RMOG	every	time”	
was	higher	in	those	treated	with	ICS	including	inhalation	than	that	in	
those	treated	without	ICS	including	inhalation.	Third,	the	proportion	
of	 “RMOG	every	 time”	was	 significantly	 higher	 in	 female	 patients	
than	that	of	male	patients	in	both	diseases.	But	age	of	the	patients	
had	nothing	to	do	with	performing	“RMOG	in	both	diseases.”	Fourth,	
with	 regard	 to	 the	 storage	 location	of	 inhaler,	we	 found	 that	 per-
forming	 “RMOG”	was	 higher	 in	 patients	 who	 stored	 inhalers	 in	 a	
room	with	 running	water	such	as	kitchen	or	bathroom	than	 in	pa-
tients	who	stored	inhalers	at	other	places.	This	difference	was	also	
found	in	both	patients	with	bronchial	asthma	and	those	with	COPD.
Local	 adverse	effects,	 such	as	hoarseness	 and	dry	mouth	asso-
ciated	with	 inhalation	therapy	or	bronchial	asthma	and	COPD,	have	
been	attributed	to	the	deposition	of	drugs	in	the	oropharynx	during	
administration.18‒20	Hira	et	al21	reported	the	relationship	between	sal-
ivary	secretion	and	hoarseness	in	232	patients	with	bronchial	asthma	
and	COPD.	According	to	their	study,	hoarseness	was	negatively	cor-
related	with	 the	volume	of	 saliva	 secreted	and	 the	dose	of	 ICS	ad-
ministrated.21 Ruffin et al22	reported	that	56%	of	the	emitted	aerosol	
dose	was	deposited	in	the	oropharynx,	and	this	might	persist	in	situ	
for	up	to	3	hours,	and	that	a	prompt	mouthwash	could	remove	60%	
of	this	residue	from	the	oropharynx.	There	were	two	previous	studies	
on	 local	adverse	effects	caused	by	 inhaled	drugs.23,24	 In	a	study	by	
Kajiwara	et	al23	with	892	patients	with	bronchial	asthma,	the	absence	
of	RMOG	after	 ICS	was	associated	with	 topical	adverse	symptoms.	
They	 reported	 that	 the	 absence	 of	 gargling	 or	mouth	washing	was	
identified	to	be	a	risk	factor	in	females	only	and	not	in	males,	when	
stratified	by	gender	in	the	multiple	regression	model.23	In	a	study	with	
6740	patients	with	bronchial	asthma	and	COPD,	Malimard	et	al24 re-
ported	the	high	prevalence	of	oropharyngeal	adverse	effects	and	the	
association	of	adherence	with	ICS	in	patients	with	COPD,	especially	
in	relatively	new	ICS	users.	In	our	present	study,	there	was	no	differ-
ence	in	the	incidence	of	local	adverse	effects	between	two	diseases,	
and	the	incidence	was	higher	in	males	than	females.	In	the	article	by	
Kajiwara	et	al,	the	majority	of	subjects	were	female,	but	only	34.8%	
were	 female	 patients	 in	 our	 study.	 In	 the	 article	 by	Malimard	 et	al,	
ICS	was	administered	 to	all	patients,	but	18	of	108	COPD	patients	
were	 received	 ICS	 including	 inhalation	 in	 our	 study.	 The	 causes	 of	
the	differences	are	beyond	our	knowledge,	but	we	suppose	that	they	
might	be	related	to	these	backgrounds	of	the	study	subjects.	Taking	
their	 results	 into	 consideration,	 in	 order	 to	 lower	 the	 frequency	 of	
local	adverse	effects,	it	can	be	necessary	to	start	guidance	of	RMOG	
at	 the	 time	 of	 starting	 ICS	 inhalation	 therapy	 for	 COPD	 patients.	
Alternatively,	as	COPD	patients	may	inhale	drugs	containing	ICS,	so	
it	may	be	desirable	for	them	to	start	guidance	of	RMOG	at	the	time	
of	starting	inhalation	therapy	regardless	of	the	type	of	inhaled	drugs.
In	our	study,	the	proportion	of	patients	who	answered	they	al-
ways	did	RMOG	was	70.3%,	which	was	higher	than	the	results	of	the	
previous	study	with	a	smaller	number	of	19	patients	who	used	ICS.25 
Recent	patient	education	may	be	related	to	 improving	the	propor-
tion	of	performing	RMOG.	However,	our	results	of	the	proportion	
of	performing	 “RMOG”	after	 inhalation	were	not	 satisfactory,	 and	
indicated	that	further	implementation	of	“patient	education”	on	per-
forming	RMOG	after	inhalation	for	patients	receiving	inhaled	medi-
cation	is	necessary.
In	the	present	study,	we	also	showed	that	performing	“RMOG”	
was	higher	 in	patients	who	stored	 inhalers	 in	a	room	with	running	
TA B L E  3  Comparison	between	222	patients	with	bronchial	
asthma	and	108	patients	with	chronic	obstructive	pulmonary	
disease	(COPD)
Bronchial 
asthma COPD P‐value
Age	(median,	range),	(y) 71,	26-95 73,	41-89 0.0194
Gender,	M/F 117/105 98/10 0.0001
Diagnosis
Asthma/COPD 182/50 40/58 0.0001
ICS-containing	drugs
Included/not included 180/2 18/90 0.0001
LAMA
LAMA	only/LAMA	and	
other	drugs
2/180 25/83 0.0001
RMOG
Every	time/sometimes	
or no
182/40 50/58 0.0001
Storage	place
Room with running 
water/other	places
89/133 38/70 0.4017
COPD,	chronic	obstructive	pulmonary	disease,	ICS,	inhaled	corticoster-
oid,	 LAMA,	 long-acting	 muscarinic	 antagonist,	 RMOG,	 rinsing	 of	 the	
mouth	and	the	oropharynx	by	gargling.
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water	such	as	kitchen	or	bathroom	than	in	patients	who	stored	in-
halers	at	other	places.	This	was	the	most	remarkable	results	of	this	
study.	To	our	best	knowledge,	there	has	been	no	report	on	the	re-
lation	between	storage	place	of	 inhaler	device	and	 the	proportion	
of	patients	with	RMOG.	We	believe	it	 is	important	to	evaluate	the	
target	 group	of	patients	 and	 to	properly	 instruct	 them.	The	 infor-
mation	on	the	relationship	between	the	storage	place	of	inhaler	and	
performing	“RMOG”	 is	 likely	 to	help	physicians	better	manage	pa-
tient	education.	To	encourage	future	enlightenment,	we	do	believe	
that	reference	to	this	result	contributes	to	improving	the	proportion	
of	RMOG.
The	current	study	has	certain	limitations.	The	study	was	without	
a	large	number	of	patients,	and	involved	patients	with	several	treat-
ment	 periods	 with	 several	 drugs	 and	 devices.	 These	 irregularities	
could	be	obstacles	to	generalizing	results.	However,	the	results	ob-
tained	in	this	study	were	those	in	unselected	patients	in	daily	clinical	
practice.	Well-planned	prospective	studies	should	be	performed	to	
confirm	the	results	of	this	study.	We	are	currently	planning	to	per-
form	such	studies.
In	conclusion,	further	implementation	of	“patient	education”	on	
performing	 RMOG	 after	 inhalation	 for	 patients	 receiving	 inhaled	
medication	is	still	necessary.	To	increase	the	proportion	of	RMOG,	it	
may	be	useful	to	propose	patients	to	store	inhalers	in	places	where	
there	is	easy	access	to	tap	water	used	for	RMOG.
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Number of patients who answered they did
“RMOG every time”
“RMOG sometimes” or 
“no RMOG” P‐value
Age	(median,	range),	(y) 72,	26-93 70,	41-95 0.6244
Gender,	M/F 87/95 30/10 0.0026
ICS-containing	drugs
Included/not included 180/2 37/3 0.0419
LAMA
LAMA	only/LAMA	and	
other	drugs
2/180 2/38 0.1496
Storage	place
Room with running 
water/other	places
86/96 3/37 0.0001
COPD,	chronic	obstructive	pulmonary	disease,	ICS,	inhaled	corticosteroid,	LAMA,	long-acting	mus-
carinic	antagonist,	RMOG,	rinsing	of	the	mouth	and	the	oropharynx	by	gargling.
TA B L E  4  Proportion	of	“RMOG	every	
time”	and	“RMOG	sometimes”	or	“no	
RMOG”	in	222	patients	with	bronchial	
asthma
Number of patients who answered they did
“RMOG every time”
“RMOG sometimes” or 
“no RMOG” P‐value
Age	(median,	range),	(y) 74,	46-87 72,	41-89 0.3845
Gender,	M/F 47/3 51/7 0.3345
ICS-containing	drugs
Included/not included 15/35 3/55 0.0006
LAMA
LAMA	only/LAMA	and	
other	drugs
6/44 20/38 0.0071
Storage	place
Room with running 
water/other	places
23/27 15/43 0.0428
COPD,	chronic	obstructive	pulmonary	disease;	ICS,	inhaled	corticosteroid;	LAMA,	long-acting	mus-
carinic	antagonist;	RMOG,	rinsing	of	the	mouth	and	the	oropharynx	by	gargling.
TA B L E  5  Proportion	of	“RMOG	every	
time”	and	“RMOG	sometimes”	or	“no	
RMOG”	in	108	patients	with	chronic	
obstructive	pulmonary	disease
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